A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis

Summary

Phase 2 clinical trial conducted in 2 parts: Part 1 - Pharmacokinetics and Part 2 - Randomized and Placebo Controlled (subject and clinical assessors will be blinded). Study Product will be applied to AD BID days 1-28. There will be weekly visits from Baseline (day 1) through Day 29. There is a final follow up visit 2 weeks after.

Timeline

Start

2023-01-08

Primary completion

2023-12-30

Completion

2024-04-15

Outcome

Outcome not reported

Stopped (Business): “Funding constraints”

Drugs

Indications